China approves AstraZeneca’s Symbicort Turbuhaler for asthma
AstraZeneca said its Symbicort Turbuhaler is the first approved dual-combination therapy for mild, moderate and severe asthma in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Jan 21
AstraZeneca said its Symbicort Turbuhaler is the first approved dual-combination therapy for mild, moderate and severe asthma in…
25 Jan 21
The FDA approval of the combination regimen is based on the results of the phase 3 CheckMate -9ER…
25 Jan 21
Pfizer and BioNTech's Covid-19 vaccine has been provisionally approved for individuals aged 16 years and above
22 Jan 21
ViiV Healthcare said that Cabenuva is the first and only complete long-acting regimen for the treatment of HIV-1…
21 Jan 21
Merck claimed that its Verquvo is the first soluble guanylate cyclase stimulator to receive FDA approval for the…
21 Jan 21
EC approval is based on results from Phase 2 DESTINY-Breast01 trial, which showed clinically meaningful and durable responses
20 Jan 21
The research and license collaboration aims to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody…
19 Jan 21
The companies claimed that their Enhertu is the first HER2-directed medicine approved for patients with gastric cancer in…
19 Jan 21
Etana will commercialise Byvasda in Indonesia, in exchange for milestone payments, and double-digit royalties on net sales of…
18 Jan 21
With the acquisition, Thermo Fisher will expand its manufacturing capabilities for cell and gene therapies